ASCO 2017 - Relapsed/refractory diffuse large B-cell lymphoma: JCAR017 achieves high CR rates in phase 1 trial

Access to the full content of this site is available only to registered healthcare professionals. Register to read more

Takeaway

  • At the lower of 2 dose levels (5×107 cells), the response rate was 80% in this phase 1 trial of the second-generation, CD 19-direted, CAR T-cell product JCAR017, with 60% achieving complete response.

Why this matters

  • JCAR017 has significant anticancer activity and a fair s...